Aurobindo Pharma is currently trading at Rs. 774.00, up by 10.90 points or 1.43% from its previous closing of Rs. 763.10 on the BSE.
The scrip opened at Rs. 769.90 and has touched a high and low of Rs. 778.45 and Rs. 769.90 respectively. So far 39,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 891.50 on 30-Dec-2015 and a 52 week low of Rs. 582.00 on 25-Feb-2016.
Last one week high and low of the scrip stood at Rs. 778.45 and Rs. 747.20 respectively. The current market cap of the company is Rs. 45,312.61 crore.
The promoters holding in the company stood at 53.79%, while Institutions and Non-Institutions held 34.67% and 11.54% respectively.
Aurobindo Pharma is reportedly aiming to achieve $3 billion in revenues in next two years. In this regard, the company will increase number of launches in the US market. Even though Aurobindo had launched as many as 28 products in the US market in the previous year, it has carried forward 7 ANDA final approvals received during the year for the launch in the current year.
The company as on March, 2016 has filed 398 ANDAs on a cumulative basis, out of which 251 ANDAs were approved including 36 tentative approvals and balance 147 ANDAs are under review by the USFDA.
